Activity of CD4+ T-cell Clones of Type 1 and Type 2 in Generation of Influenza Virus-specific Cytotoxic Responses in Vitro
Overview
Authors
Affiliations
The activity of distinct CD4+ T-helper cell (Th) clones in promoting secondary A/PR/8/34/Mt.S.(H1N1) (A/PR8) influenza virus-specific, class I-restricted cytotoxic T-lymphocyte (CTL) responses in vitro was examined. CD8+ T cells which had been purified by fluorescence-activated cell sorter from spleen cells of A/PR8-primed mice were used as responders. On their own, purified CD8+ T cells were unable to generate cytotoxic activity upon in vitro culture with A/PR8-infected stimulator cells. Significant cytotoxic activity was generated in cultures that were additionally supplemented with A/PR8-specific Th clones or cell-free supernatant from these clones. Although there were large differences among individual Th clones in this function, Th clones of type 1 (Th1) promoted, on average, significantly stronger cytotoxic responses than Th clones of type 2 (Th2). The differences in promotion of a cytotoxic response correlated with the amount of interleukin-2 (IL-2) or IL-4 secreted by individual Th clones. These two lymphokines accounted for the CTL-promoting activity of the respective Th clones, since addition of recombinant IL-2 (IL-2) or rIL-4 to Th-free cultures substituted fully for the respective Th clones. As observed with Th clones, rIL-2 was significantly more effective than rIL-4 in promoting a cytotoxic response. When used in combination, Th2 clones had an antagonistic effect on the generation of a CTL response by Th1 clones. This effect could be partially transferred with cell-free supernatant from activated Th2 clones and could be reversed by addition of excess rIL-2. Both consumption of IL-2 by Th2 and secretion of an inhibitory factor(s) appear to be involved in this phenomenon.
A computational approach to design a multiepitope vaccine against H5N1 virus.
Dashti F, Raisi A, Pourali G, Razavi Z, Ravaei F, Nahand J Virol J. 2024; 21(1):67.
PMID: 38509569 PMC: 10953225. DOI: 10.1186/s12985-024-02337-7.
Designing a multi-epitope vaccine to provoke the robust immune response against influenza A H7N9.
Tarrahimofrad H, Rahimnahal S, Zamani J, Jahangirian E, Aminzadeh S Sci Rep. 2021; 11(1):24485.
PMID: 34966175 PMC: 8716528. DOI: 10.1038/s41598-021-03932-2.
Brenna E, Davydov A, Ladell K, McLaren J, Bonaiuti P, Metsger M Cell Rep. 2020; 30(1):137-152.e5.
PMID: 31914381 PMC: 7029615. DOI: 10.1016/j.celrep.2019.12.016.
Rumke H, Richardus J, Rombo L, Pauksens K, Plassmann G, Durand C BMC Infect Dis. 2013; 13:348.
PMID: 23890405 PMC: 3729430. DOI: 10.1186/1471-2334-13-348.
Hallmarks of CD4 T cell immunity against influenza.
McKinstry K, Strutt T, Swain S J Intern Med. 2011; 269(5):507-18.
PMID: 21362069 PMC: 3395075. DOI: 10.1111/j.1365-2796.2011.02367.x.